skip to Main Content

Dr. Choti on the Benefits of Neoadjuvant Chemotherapy in Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Michael A. Choti, MD, chief of surgery, Banner MD Anderson Cancer Center, discusses the benefit of neoadjuvant chemotherapy in pancreatic cancer.

Although the guidelines for pancreatic cancer suggest up-front surgery, data from recent studies are making it clear that neoadjuvant chemotherapy is superior to up-front surgery, particularly with regard to a pancreaticoduodenectomy. Neoadjuvant chemotherapy provides patients with the opportunity to receive the therapy, explains Choti. Read more . . . 

Back To Top